NIH: Investigational COVID-19 vaccine generally well tolerated and prompted neutralizing antibody activity
by Press Release from Outbreak News Today on (#55QTG)
An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine. The ongoing Phase 1 trial is supported by the National Institute of Allergy [...]
The post NIH: Investigational COVID-19 vaccine generally well tolerated and prompted neutralizing antibody activity appeared first on Outbreak News Today.